RichardBarryWilderMD, MS, MBA
Radiation Oncology • Boca Raton, FLBreast Cancer, Hematologic Malignancies, Skin Cancer, Urologic Cancer
Physician Clinical Reviewer, Radiation Oncology at Evolent Health, Inc
Dr. Wilder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Evolent Health, Inc
8999 Dulcetto Ct
Boca Raton, FL 33496- Is this information wrong?
Summary
- I am a board-certified radiation oncologist who completed residency and fellowship training in 1993. I served on the NCCN Guidelines kidney and testicular cancer panel, helped to develop Moffitt Cancer Center's clinical pathways, served on the Lymphoma/Leukemia Committee wherein I wrote questions for the written exam and gave the oral exam for the for the American Board of Radiology, rose to the rank of Professor and worked as a tenured Interim Chair of the Moffitt Cancer Center in Tampa, FL, served as principal investigator on 8 clinical trials, published 92 peer-reviewed articles, gave 73 oral and poster presentations at meetings and helped to train 72 residents and fellows. Since 2016, I have worked in radiation oncology benefits management.
In January 2023, Evolent Health completed its acquisition of National Imaging Associates (NIA; also known as Magellan Health) from Centene Corporation. Centene and Evolent have a multi-year strategic partnership to expand Evolent's Oncology and End of Life solutions for health plans. NIA is a national leader in managing specialty care under risk-based, capitated relationships. Its mission is to transform the delivery of specialty care by partnering with health plans and providers to drive improvements in the quality and cost of care. Currently, NIA has over 5,000 employees, including 132 MDs and RNs and 588 social workers, who work with 80 health plans that have 21 million members. In January 2023, Evolent Health completed its acquisition of NIA from Centene Corporation. As a member of Evolent Health's utilization management team, I provide timely review of radiation oncology and radiology service requests that do not initially meet the applicable medical necessity guidelines. I routinely interact with other physicians, Evolent Health's leadership and management staff as well as health plan staff.
Education & Training
Johns Hopkins University Carey Business SchoolMBA, Finance, 2006 - 2008
University of Arizona College of Medicine-TucsonResidency, Radiation Oncology, 1989 - 1993
Stanford Health CareFellowship, ASTRO Research Fellow, Department of Radiation Oncology, 1991 - 1992
Greater Baltimore Medical CenterInternship, Internal Medicine, 1988 - 1989
University of Maryland School of MedicineClass of 1988- Stanford UniversityM.S., Biological Sciences
- Stanford UniversityB.S., Biological Sciences and Chemical Engineering
Certifications & Licensure
FL State Medical License 2009 - 2026
TX State Medical License 2000 - 2024
CA State Medical License 1991 - 2024
GA State Medical License 2015 - 2018- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Lifetime Service Award American Board of Radiology, 2018
- Association of Residents in Radiation Oncology Teacher of the Year Award National Capital Consortium/National Cancer Institute, 2004
- Departmental Honors in Biological Sciences Stanford University
- Join now to see all
Clinical Trials
- Cross-linked Hyaluronan Gel Reduces Rectal Toxicity Due to Radiation Therapy for Prostate Cancer Start of enrollment: 2008 Sep 01
Publications & Presentations
PubMed
- Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancer.Casey Liveringhouse, Austin J. Sim, Kosj Yamoah, Michael A. Poch, Richard B. Wilder, Julio M. Pow-Sang, Peter A.S. Johnstone> ;Reports of Practical Oncology and Radiotherapy. 2021 Apr 14
- 11 citationsRectal dose to prostate cancer patients treated with proton therapy with or without rectal spacer.H Chung, Jerimy C. Polf, Shahed N. Badiyan, Matthew C. Biagioli, Daniel C. Fernandez, Kujtim Latifi, Richard B. Wilder, Minesh P. Mehta, Michael D. Chuong> ;Journal of Applied Clinical Medical Physics. 2017 Jan 1
- 9 citationsHealth-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.Tobin Strom, Alex Cruz, Nicholas Figura, Kushagra Shrinath, Kevin Nethers, Eric A. Mellon, Daniel C. Fernandez, Amarjit S. Saini, Dylan Hunt, Randy V. Heysek, Richard ...> ;Brachytherapy. 2015 Nov 1
- Join now to see all
Journal Articles
- Kidney cancer, version 3Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, ..., Journal of the National Comprehensive Cancer Network, 1/1/2015
- Testicular Cancer, Version 2Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, ..., Journal of the National Comprehensive Cancer Network, 1/1/2015
- Kidney cancer, version 2Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Li..., Journal of the National Comprehensive Cancer Network, 1/1/2014
- Join now to see all
Books/Book Chapters
Lectures
- Phase III RTOG protocols for head and neck cancerU. C. Davis Medical Center, Sacramento, CA - 1/21/1996
- Radiation Therapy and Dosimetry SchoolsSouthwestern Moncrief Cancer Center in Fort Worth, TX; The Medical Branch in Galveston, TX; The Scot
- Stereotactic radiosurgeryMultiple locations
- Join now to see all
Other
- Radiotherapy treatment planning for testicular seminomaWilder RB, �Beyond the Abstract.� UroToday
http://www.urotoday.com/index.php?option=com_content&Itemid=847&catid=1158&id=56713&lang=en&view=article
1/10/2013 - ACR Appropriateness Criteria�: Hodgkin�s Lymphoma�Stage III and IVWilder RB, Ng A, Constine LS, Advani R, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilson LD, Yunes MJ, American College of Radiology
http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonRadiationOncologyHodgkinsWorkGroup/StageIIIandIVHodgkinsDiseaseUpdateinProgressDoc6.aspx
1/1/2011 - American College of Radiology. (2011, September 1). ACR Appropriateness Criteria�: Favorable prognosis stage I-II Hodgkin�s lymphomaDas P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ, American College of Radiology
http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonRadiationOncologyHodgkinsWorkGroup/FavorablePrognosisStageIandIIHodgkinsDiseaseUpdateinProgressDoc1.aspx
1/1/2011 - Join now to see all
Press Mentions
Ensuring Equitable Access to COVID-19 VaccinesDecember 1st, 2020
Committees
- Chair, ASTRO's FDA Subcommittee 2015 - 2017
- Member (radiation oncology representative for national guidelines), National Comprehensive Cancer Network Kidney and Testicular Cancer Panel 2010 - 2015
- Member, Lymphoma/Leukemia Committee, American Board of Radiology 2002 - 2021
Professional Memberships
- Member
External Links
- LinkedInhttps://www.linkedin.com/in/richardwildermdmedicalreserch/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
